Related Experiment Video

Updated: Apr 4, 2026

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
11:32

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

15.7K

Impacts of the 13-Valent Pneumococcal Conjugate Vaccine in Children

Susanna Esposito1, Nicola Principi1

  • 1Pediatric Highly Intensive Care Unit, Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Via Commenda 9, 20122 Milan, Italy.

Journal of Immunology Research
|September 10, 2015
PubMed

Insights

The 13-valent pneumococcal conjugate vaccine (PCV13) offers broader protection against pneumococcal diseases than the 7-valent version (PCV7). PCV13 effectively reduces invasive pneumococcal diseases, mucosal infections, and carriage in children.

Area of Science:

  • Pediatric infectious diseases
  • Vaccinology
  • Immunology

Background:

  • Heptavalent pneumococcal conjugate vaccine (PCV7) significantly reduced pneumococcal diseases.
  • Emerging non-PCV7 serotypes increased, necessitating broader vaccine coverage.
  • New vaccines were developed to address serotype replacement.

Purpose of the Study:

  • To review the impact of the 13-valent pneumococcal conjugate vaccine (PCV13) on pneumococcal disease control in children.
  • To compare the efficacy of PCV13 with PCV7.

Main Methods:

  • Review of global evaluation studies on PCV13 application in pediatric immunization schedules.
  • Analysis of data on invasive pneumococcal diseases, mucosal pneumococcal diseases, and pneumococcal carriage.

Main Results:

  • PCV13 covers 7 PCV7 serotypes plus 6 additional serotypes (1, 3, 5, 6A, 7F, 19A).
  • PCV13 demonstrated wider coverage and more effective prevention against pneumococcal diseases compared to PCV7.
  • Studies showed PCV13's efficacy in reducing invasive pneumococcal diseases, mucosal pneumococcal diseases, and pneumococcal carriage.

Conclusions:

  • PCV13 provides enhanced protection against pneumococcal diseases in children.
  • PCV13 is a valuable tool for controlling pneumococcal infections beyond the scope of PCV7.
  • Continued surveillance and evaluation of PCV13 impact are essential.

More Related Videos

Opsono-Adherence Assay to Evaluate Functional Antibodies in Vaccine Development Against Bacillus anthracis and Other Encapsulated Pathogens13:47

Opsono-Adherence Assay to Evaluate Functional Antibodies in Vaccine Development Against Bacillus anthracis and Other Encapsulated Pathogens

Published on: May 19, 2020

3.9K
Constructing Mutants in Serotype 1 Streptococcus pneumoniae strain 519/4306:06

Constructing Mutants in Serotype 1 Streptococcus pneumoniae strain 519/43

Published on: September 11, 2020

2.3K

Related Concept Videos

Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
804
Vaccinations01:51

Vaccinations

Overview
54.0K
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
337
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
482
Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
1.2K
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
750